Sigilon Therapeutics SGTX

$ 22.47 0.0%

Quarterly report 2023-Q2
added 08-07-2023

Sigilon Therapeutics Financial Statements 2011-2024 | SGTX

Annual Financial Statements Sigilon Therapeutics

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	39.9 M	46.2 M	405 M	-	-	-	-	-	-	-	-	-
Shares	32.4 M	31.9 M	13.2 M	-	-	-	-	-	-	-	-	-
Historical Prices	1.23	1.45	26.6	-	-	-	-	-	-	-	-	-
Net Income	-43.6 M	-77.3 M	-54.6 M	-43.9 M	-22.8 M	-	-	-	-	-	-	-
Revenue	12.9 M	9.6 M	13.4 M	14.2 M	4.64 M	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	13.4 K	-	-	-	-	-	-	-	-	-
Operating Income	-43.7 M	-75.6 M	-52.6 M	-	-	-	-	-	-	-	-	-
Interest Expense	2.29 M	1.99 M	1.2 M	-	-	-	-	-	-	-	-	-
EBITDA	-42.4 M	-74.5 M	-51.8 M	-43.4 M	-22.7 M	-	-	-	-	-	-	-
Operating Expenses	56.6 M	85.2 M	66 M	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	19 M	20.2 M	12.5 M	10.2 M	6.67 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Sigilon Therapeutics

	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	2.5 M	32.5 M	2.5 M	32.4 M	2.49 M	32.4 M	32.4 M	32.1 M	31.6 M	31.5 M	31.5 M	5.34 M	5.32 M	4.98 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-7.51 M	-7.38 M	-	-8.67 M	-14.3 M	-13.9 M	-	-20.2 M	-20.4 M	-19 M	-	-54.6 M	-54.6 M	-54.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	5.9 M	4.86 M	-	4.25 M	2.88 M	3.16 M	-	1.95 M	2.7 M	2.96 M	-	4.2 M	1.95 M	3.47 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-7.44 M	-7.25 M	-	-8.42 M	-14 M	-13.5 M	-	-19.7 M	-20 M	-18.6 M	-	-12.6 M	-13.3 M	-12.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	310 K	611 K	-	606 K	543 K	491 K	-	499 K	494 K	488 K	-	293 K	196 K	208 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-7.14 M	-6.93 M	-	-8.12 M	-13.7 M	-13.2 M	-	-19.4 M	-19.7 M	-18.3 M	-	-12.4 M	-13.1 M	-12.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	13.3 M	12.1 M	-	12.7 M	16.9 M	16.6 M	-	21.7 M	22.7 M	21.5 M	-	16.8 M	15.3 M	16.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	5.88 M	4.32 M	-	4.4 M	5.04 M	5.02 M	-	5.04 M	4.99 M	5.54 M	-	3.33 M	2.82 M	2.87 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency